Jeremie Calais, MD, PhD, a physician specializing in nuclear medicine and an associate professor at the University of California, Los Angeles (UCLA), recently spoke about the controversies and unresolved questions in the treatment of patients with prostate cancer.
During the 2024 US Prostate Cancer Conference (USPCC), medical oncologists, urologists, and various other professionals gathered to share valuable knowledge and enhance the care provided to patients with prostate cancer. Calais highlighted the importance of addressing controversies within the field and the benefits of a multidisciplinary approach to patient care.
Prostate cancer is becoming increasingly complex, with advancements in diagnostics, biomarkers, and treatment options. This complexity leads to uncertainties and the need for ongoing exploration and collaboration among specialists. Calais emphasized the importance of optimizing PET imaging and utilizing prostate-specific membrane antigen–targeted radiopharmaceutical therapy to improve treatment outcomes.
Overall, discussions at the conference focused on the evolving landscape of prostate cancer treatment and the importance of interdisciplinary collaboration to address emerging questions and challenges. Calais encouraged further exploration and collaboration among specialists to enhance patient care and outcomes in the field of nuclear medicine.
